Gabelli Funds’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Gabelli Funds’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-73,303	Closed	-$733K	–	1439
2021 Q2	$733K	Buy	73,303 +12,330	+20%	+$123K	﹤0.01%	974
2021 Q1	$613K	Buy	+60,973	New	+$609K	﹤0.01%	992

Other funds holding EBACU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Gabelli Funds's EBACU Position: Q3 2021 in Review

Gabelli Funds sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 73,303 shares — an estimated $733K sold.

Gabelli Funds first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $733K in Q2 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

Gabelli Funds reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
Gabelli Funds sold 73,303 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $733K.
Gabelli Funds first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
Gabelli Funds's European Biotech Acquisition Corp. Units position peaked at $733K in Q2 2021.
30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on Gabelli Funds's 13F filing for Q3 2021, filed 12 Nov 2021.